Wacker Biotech GmbH (Jena, Germany) have announced that they will manufacture the active ingredient in the drug Retavase®. This drug has obtained FDA approval to treat acute myocardial infarction in adults.
The first biosimilar for the treatment of breast and stomach cancers has been approved by the FDA, termed Ogivri.
In this commentary, Melanie Anderson discusses the use of paper-based dried sampling technologies and how they can provide opportunities to collect biological samples in the dried state, which involves significantly smaller sample volumes than traditional sample collection approaches.
Lonza (Basel, Switzerland) announce the launch of four new services to expand their early phase biopharmaceutical drug development.
2. Given the complexity and cost of development and manufacturing, are biosimilars more affordable therapeutic options?
In this ‘Ask the Experts’ feature, the experts discuss the complexity and cost of development and whether biosimilars are more affordable therapeutic options.
12. How do you see the field evolving over the next 5-10 years? What are the main obstacles to be overcome?
In our final instalement, our experts look towards the future and comment on how they see the field evolving over the next 5-10 years.
Available to view on demand: In this webinar, Glenn Petrie discusses best practice in optimizing the Chemistry, Manufacturing and Control (CMC) process.
Available to view on demand
In this presentation, the results of an exploration of HRMS for the quantitative determination of biopharmaceutical proteins and a comparison to nominal mass LC-MS/MS will be provided, including validation results and application to preclinical trials.
Meeting Report: 30th International Symposium, Exhibit and Workshops on Preparative and Process Chromatography
The 30th International Symposium, Exhibit was held in Philadelphia, PA, on July 16-19, 2017 at the Loews Hotel.The symposium was attended by more than 320 people from 21 different countries
Available to view on demand: In this webinar, Glenn Petrie discusses the key to rapid investigational new drug submission and approval in ADC developlment.